Isonipecotic acid
Isonipecotic acid is a heterocyclic compound which acts as a GABAA receptor partial agonist.[1]
| |||
| Names | |||
|---|---|---|---|
| IUPAC name
4-Piperidinecarboxylic acid | |||
| Identifiers | |||
CAS Number |
| ||
3D model (JSmol) |
|||
| ChEMBL | |||
| ChemSpider |
| ||
| ECHA InfoCard | 100.007.158 | ||
| EC Number |
| ||
IUPHAR/BPS |
|||
PubChem CID |
|||
| UNII | |||
CompTox Dashboard (EPA) |
|||
InChI
| |||
SMILES
| |||
| Properties | |||
Chemical formula |
C6H11NO2 | ||
| Molar mass | 129.16 g/mol | ||
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |||
| Infobox references | |||
It consists of a piperidine ring with a carboxylic acid moiety in the iso position (and as such is also known as "4-piperidinecarboxylic acid").
References
- Mortensen M, Kristiansen U, Ebert B, Frølund B, Krogsgaard-Larsen P, Smart TG (June 2004). "Activation of single heteromeric GABA(A) receptor ion channels by full and partial agonists". The Journal of Physiology. 557 (Pt 2): 389–413. doi:10.1113/jphysiol.2003.054734. PMC 1665090. PMID 14990676.
Hypnotics/sedatives (N05C) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GABAA |
| ||||||||||||||||||||||||
| GABAB |
| ||||||||||||||||||||||||
| H1 |
| ||||||||||||||||||||||||
| α2-Adrenergic |
| ||||||||||||||||||||||||
| 5-HT2A |
| ||||||||||||||||||||||||
| Melatonin | |||||||||||||||||||||||||
| Orexin |
| ||||||||||||||||||||||||
| α2δ VDCC |
| ||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||
GABA receptor modulators | |||||
|---|---|---|---|---|---|
| Ionotropic |
| ||||
| Metabotropic |
| ||||
| |||||
Glycine receptor modulators | |||||
|---|---|---|---|---|---|
| Receptor (ligands) |
| ||||
| Transporter (blockers) |
| ||||
| |||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

